TVTX — Travere Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1438533 ·
Last close
$51.10
Market Cap
$4.91B
52W High
$68.73
52W Low
$22.59
ADV30
2,086,610
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 224,563,000 | 213,728,000 | 45,010,000 | -52,337,000 | 848,229,000 | 123,542,000 | 825,645,000 |
| Jun 2026 | 169,584,000 | 160,349,000 | 3,954,000 | -34,797,000 | 799,360,000 | 117,735,000 | 774,838,000 |
| Mar 2026 | 127,199,000 | 100,433,000 | -36,915,000 | -37,102,000 | 555,188,000 | 78,362,000 | 456,460,000 |
| Dec 2025 | 129,689,000 | 127,136,000 | -32,428,000 | 2,729,000 | 605,191,000 | 93,035,000 | 490,363,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$153,087,000
Investing CF
$-409,203,000
Financing CF
$245,688,000
CapEx
$-203,978,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.29
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,596,949,000
Inventory
$10,516,000
Receivables
$107,528,000
ST Investments
$348,276,000
EBIT TTM
$-150,850,000
Pretax Income TTM
$-159,720,000
Interest Exp TTM
$8,870,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$651,033,984
EBITDA
$32,403,000
Free Cash Flow
$-64,789,248
Enterprise Value
$4,905,547,776
Total Cash
$471,817,984
Total Debt
$616,155,008
Shares Out
95,992,155
Trailing EPS
$-1.67
Book Value
$0.24
ROE
-321.2%
ROA
-1.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 490,728,000 | -62,824,000 | -25,546,000 | 605,191,000 | 490,363,000 | 114,828,000 | 37,784,000 |
| Dec 2024 | 233,175,000 | -321,389,000 | -321,545,000 | 594,125,000 | 535,048,000 | 59,077,000 | -237,475,000 |
| Dec 2023 | 145,238,000 | -376,744,000 | -111,399,000 | 788,913,000 | 588,103,000 | 200,810,000 | -280,021,000 |
| Dec 2022 | 109,460,000 | -319,813,000 | -278,482,000 | 672,585,000 | 629,734,000 | 42,851,000 | -186,291,000 |
TTM Snapshot
Revenues TTM
$591,330,000
NetIncome TTM
$-43,464,000
OpCashFlow TTM
—
Assets (Latest)
$799,360,000
Forward EPS
$5.28
Max Pain — expiry 2027-01-15
max pain strike: $30.00 · spot: $50.24 · call oi: 13,290 · put oi: 3,385
Expected Move to 2027-01-15:
±$6.42
(12.79%) —
implied range
$43.82 –
$56.67
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.90B | $86.98 | — |
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.04B | $60.36 | — |
| LQDA | Liquidia Corp | $5.11B | $56.73 | — |
News headlines (Yahoo Finance, 1h cache)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-12 22:00 · Yahoo
Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why
2026-11-03 21:36 · Yahoo
Travere Therapeutics to Participate at Upcoming Investor Conferences
2026-11-03 21:30 · Yahoo
Why Travere Therapeutics (TVTX) Could Be 34% Undervalued On Its Q3 Loss
2026-11-03 08:10 · Yahoo
Travere Therapeutics (TVTX) Stock Looks Fully Priced After Its 7x Run
2026-11-03 07:06 · Yahoo
What Could Travere Therapeutics (TVTX) New Biomarker Data Mean For IgA Nephropathy?
2026-11-03 06:14 · Yahoo
Travere: Q3 Earnings Snapshot
2026-11-03 04:37 · Yahoo
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
2026-11-03 00:14 · Yahoo
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
2026-11-02 22:30 · Yahoo
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
2026-11-02 21:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.